Clinical trials
Psilocybin clinical trials
Below are recruiting psilocybin clinical trials, each written for real people, not researchers. We’re tracking 103 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06796361RecruitingPhase 1
Psilocybin's effect on consciousness: serotonin receptor role
This study tests how psilocybin (the active ingredient in magic mushrooms) affects consciousness by blocking a specific serotonin receptor in the brain. It helps researchers understand why psilocybin causes altered states of mind.
Basel, Canton of Basel-CityAges 25–75 - NCT07638553RecruitingPhase 3
Psilocybin to prevent alcohol relapse with depression
This study tests whether psilocybin (a psychedelic compound) can help people with severe alcohol use disorder stay sober longer, especially if they also have depression. Participants receive guided psilocybin sessions alongside counseling to reduce the risk of returning to heavy drinking.
BayonneAges 18 years+ - NCT07347405RecruitingPhase 1
Psilocybin Whole Mushroom for OCD Treatment
This trial tests a whole-mushroom version of psilocybin as a potential treatment for OCD that hasn't improved with standard therapies. Participants receive psilocybin in a controlled setting and are monitored closely for safety and changes in symptoms.
Tucson, ArizonaAges 18 years+ - NCT07210112RecruitingPhase 2
Psilocybin and Trazodone for tough-to-treat depression
This trial tests if taking psilocybin (a psychedelic drug) with trazodone (an antidepressant) can help people whose depression hasn't improved with at least two standard antidepressants. If you have treatment-resistant depression, this study might be an option.
ParisAges 18 years+ - NCT07211438RecruitingPhase 2
Psilocybin with Monitors for Treatment-Resistant Depression
This study tests whether trained monitors improve the safety and outcomes of psilocybin therapy for people with depression that hasn't responded to other treatments. Participants will receive psilocybin in a supervised setting and will need to temporarily stop other psychiatric medications.
Toronto, OntarioAges 18–70 - NCT07180108RecruitingPhase 1
Psilocybin and music study for healthy volunteers
This study tests how music affects your experience with psilocybin, a psychedelic substance. It may help researchers understand how to create the best setting for psilocybin therapy.
Baltimore, MarylandAges 21–75 - NCT07104916RecruitingPhase 2
Mindfulness and psilocybin therapy for PTSD
This study tests whether a combination of mindfulness training and a single dose of psilocybin can help reduce PTSD symptoms. It is for people with moderate-to-severe PTSD who are not on certain medications and do not have major health problems.
Columbus, OhioAges 21–65 - NCT06592833RecruitingPhase 2
Psilocybin with or without pimavanserin for depression
This study tests whether combining psilocybin (a psychedelic substance) with pimavanserin (a medication that may help reduce side effects) works better than psilocybin alone for treating major depressive disorder. It may help people who have not responded well to other treatments.
New York, New YorkAges 21–80 - NCT06943573RecruitingPhase 2
Psilocybin therapy for bipolar ii depression
This study tests whether a psychedelic drug called psilocybin (the active ingredient in 'magic' mushrooms), combined with therapy, can help relieve depression in people with bipolar II disorder who haven't gotten better with other treatments. You'll receive the drug in a supervised setting and attend follow-up visits to see how it affects your mood.
Vancouver, British ColumbiaAges 19–65 - NCT06888128RecruitingPhase 2
Psilocybin for PTSD in veterans
This study tests whether a guided psilocybin session can help veterans heal from trauma-related PTSD. If you're a veteran with PTSD, you may be able to join.
Houston, TexasAges 21–64 - NCT06810310RecruitingPhase 2
Psilocybin for motivation in opioid use disorder
This study tests whether a single dose of psilocybin (the active ingredient in magic mushrooms) can help people with opioid use disorder stay motivated in recovery. It uses brain scans to see how psilocybin affects brain areas linked to motivation.
Philadelphia, PennsylvaniaAges 18–60 - NCT06768944RecruitingPhase 2
Psilocybin and Subjective Experience Study
This study looks at how psilocybin affects people's subjective experience. It aims to understand the mind-altering effects of this psychedelic compound in healthy volunteers.
Calgary, AlbertaAges 18–65 - NCT06692192RecruitingPhase 1
Midazolam and psilocybin for wellbeing study
This trial tests how two different drugs, midazolam and psilocybin, affect the brain and wellbeing. It may help if you feel your wellbeing has dropped a bit but you don't have a diagnosed mood or anxiety disorder.
Madison, WisconsinAges 18–65 - NCT06319378RecruitingPhase 2
Psilocybin for cancer-related depression
This trial tests whether a single dose of psilocybin, a psychedelic medication, can safely and effectively treat major depression in people with cancer. If you have cancer and have been feeling depressed for at least a month, you may qualify.
Gothenburg, GöteborgAges 20–80 - NCT06200155RecruitingPhase 2
Psilocybin therapy for advanced cancer patients with anxiety or depression
This trial tests whether a drug called psilocybin, given with therapy, can help people with advanced cancer who are feeling anxious or depressed. You must have a stable cancer and be willing to travel to Houston for treatment.
Houston, TexasAges 25 years+ - NCT06132178RecruitingPhase 2
Psilocybin and rTMS for hard-to-treat depression
This study tests whether a combination of psilocybin (a psychedelic substance) and transcranial magnetic stimulation (rTMS, a noninvasive brain stimulation) can help people with treatment-resistant depression. It involves daily visits to the research center for about 2 weeks.
Austin, TexasAges 22–65 - NCT07721467RecruitingPhase 2
Cognitive training with psilocybin for brain flexibility
This study tests whether combining a brain-training program with a psychedelic drug called psilocybin can boost the brain's ability to change and adapt. It may help improve thinking and memory.
Baltimore, MarylandAges 65–120 - NCT05995769RecruitingPhase 2
Psilocybin therapy with talk therapy for alcohol problems
This trial tests whether psilocybin (the active ingredient in magic mushrooms), given with talk therapy, can help people who want to reduce their heavy drinking. It is for people with at least moderate alcohol use disorder who are motivated to change.
Calgary, AlbertaAges 22–65 - NCT07818564RecruitingPhase 1
Psilocybin study on belief and insight in healthy adults
This study tests whether a single dose of psilocybin (a psychedelic compound) can help people update their beliefs and gain new insights. It's for healthy adults with some prior psychedelic experience, and it's a small pilot study at Brown University.
Providence, Rhode IslandAges 18 years+ - NCT06378229RecruitingPhase 2
Psilocybin for hospitalized treatment-resistant depression
This trial tests whether a single dose of psilocybin can help hospitalized patients with tough-to-treat depression. It focuses on people who haven't improved with standard antidepressants and need a new option.
Ghent, Oost-VlaanderenAges 18 years+ - NCT07737054RecruitingEarly Phase 1
Psilocybin therapy for PTSD
This trial tests a type of therapy that uses psilocybin (a safe, natural substance found in certain mushrooms) to help people with PTSD. It combines talk therapy with the medicine to see if it can reduce trauma symptoms.
Tel AvivAges 21–65 - NCT07732166RecruitingEarly Phase 1
Psilocybin and Self-Awareness Study
This trial tests whether a single dose of psilocybin (a psychedelic substance) can change self-awareness in healthy adults. It aims to understand how this substance affects the brain, which might lead to new mental health treatments.
Rio de Janeiro, Rio de JaneiroAges 21–60 - NCT07703722RecruitingPhase 3
Psilocybin and therapy for depression with trauma
This trial tests psilocybin (a compound from certain mushrooms) combined with a structured therapy to see if it helps people with depression linked to trauma. It focuses on how the treatment affects the connection between the gut and brain.
Islamabad, CapitalAges 18–60 - NCT07610369RecruitingPhase 2
Psilocybin therapy for depression in Parkinson's disease
This study tests whether psilocybin (a psychedelic compound) combined with therapy can reduce depression in people with Parkinson's disease. If you have moderate-to-severe depression and Parkinson's, this trial may offer a new treatment option.
New Haven, ConnecticutAges 40–80
Hear when a new Psilocybin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psilocybin?
- Yes. Clin2 currently lists 103 recruiting psilocybin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psilocybin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psilocybin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.